West Pharmaceutical Services (NYSE:WST) VP Sells $2,772,489.35 in Stock

West Pharmaceutical Services, Inc. (NYSE:WST) VP Annette Favorite sold 8,135 shares of the business’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $340.81, for a total value of $2,772,489.35. Following the sale, the vice president directly owned 16,845 shares in the company, valued at $5,740,944.45. This trade represents a 32.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

West Pharmaceutical Services Trading Up 0.4%

NYSE:WST opened at $345.49 on Friday. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a 1-year low of $223.83 and a 1-year high of $386.00. The firm has a market capitalization of $24.32 billion, a price-to-earnings ratio of 44.24, a price-to-earnings-growth ratio of 2.42 and a beta of 1.14. The stock has a fifty day simple moving average of $348.46 and a 200 day simple moving average of $310.28.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.08 by $0.29. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The firm had revenue of $872.30 million for the quarter, compared to the consensus estimate of $839.98 million. During the same quarter in the previous year, the company earned $1.84 EPS. The business’s revenue for the quarter was up 13.8% compared to the same quarter last year. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Sell-side analysts forecast that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current year.

West Pharmaceutical Services Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, August 5th. Stockholders of record on Wednesday, July 29th were issued a dividend of $0.22 per share. The ex-dividend date was Wednesday, July 29th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.3%. West Pharmaceutical Services’s payout ratio is currently 11.27%.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. Morgan Stanley lifted their price objective on shares of West Pharmaceutical Services from $325.00 to $365.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 9th. Evercore restated an “outperform” rating and issued a $425.00 target price on shares of West Pharmaceutical Services in a report on Monday, July 27th. UBS Group raised their target price on West Pharmaceutical Services from $340.00 to $415.00 and gave the stock a “buy” rating in a research report on Wednesday. Weiss Ratings upgraded West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, August 7th. Finally, Stephens reissued an “overweight” rating and set a $360.00 price target on shares of West Pharmaceutical Services in a research report on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $373.85.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Elyxium Wealth LLC acquired a new stake in shares of West Pharmaceutical Services during the 4th quarter valued at $25,000. CYBER HORNET ETFs LLC acquired a new position in shares of West Pharmaceutical Services in the second quarter worth $25,000. Cornerstone Planning Group LLC raised its holdings in shares of West Pharmaceutical Services by 90.9% during the first quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 50 shares in the last quarter. Bayban purchased a new stake in shares of West Pharmaceutical Services during the fourth quarter worth $27,000. Finally, Avalon Trust Co acquired a new stake in West Pharmaceutical Services during the second quarter valued at $28,000. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc (NYSE: WST) develops and manufactures components and systems used to package, contain and deliver injectable medicines and other healthcare products. Its customers include pharmaceutical, biotechnology and medical device companies, which use West products in drug administration and medical applications.

The company’s offerings include elastomer components such as stoppers, plungers and seals; syringe and cartridge components; vial and container closure systems; and specialized delivery systems for injectable and other complex medicines.